BRPI0512342A - métodos para aumento ósseo - Google Patents
métodos para aumento ósseoInfo
- Publication number
- BRPI0512342A BRPI0512342A BRPI0512342-9A BRPI0512342A BRPI0512342A BR PI0512342 A BRPI0512342 A BR PI0512342A BR PI0512342 A BRPI0512342 A BR PI0512342A BR PI0512342 A BRPI0512342 A BR PI0512342A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- bone
- pyk2
- optionally
- determining whether
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 210000000988 bone and bone Anatomy 0.000 title abstract 3
- 230000003416 augmentation Effects 0.000 title 1
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 abstract 4
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 210000000963 osteoblast Anatomy 0.000 abstract 2
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 208000002607 Pseudarthrosis Diseases 0.000 abstract 1
- 230000004097 bone metabolism Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000028169 periodontal disease Diseases 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
MéTODOS PARA AUMENTO óSSEO. A presente invenção se refere a métodos de estimulação da função de osteoblastas com um inibidor de PYK2 em indivíduos com osteoporase, fraturas ásseas, não-uniões, pseudoartroses, doença periodontal ou outros distúrbios do metabolismo ósseo. Opcionalmente, o método ainda A presente invenção também se refere a métodos para identificar um inibidor de PYK2 eficaz como um agente ósseo terapêutico compreendendo administração de um agente de teste a uma célula semelhante a osteoblasto e determinação se a função de osteoblasto é estimulada. Opcionalmente, o método de identificação ainda compreende contato do agente de teste com PYK2 e determinação se a atividade de PYK2 é inibida.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58140704P | 2004-06-21 | 2004-06-21 | |
| PCT/IB2005/002127 WO2005123191A1 (en) | 2004-06-21 | 2005-06-10 | Pyk2 inhibitors for stimulation of osteoblast function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0512342A true BRPI0512342A (pt) | 2008-03-04 |
Family
ID=35240963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0512342-9A BRPI0512342A (pt) | 2004-06-21 | 2005-06-10 | métodos para aumento ósseo |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090118316A1 (pt) |
| EP (1) | EP1765461A1 (pt) |
| JP (1) | JP2008503561A (pt) |
| AR (1) | AR049922A1 (pt) |
| BR (1) | BRPI0512342A (pt) |
| CA (1) | CA2571482A1 (pt) |
| MX (1) | MXPA06015170A (pt) |
| TW (1) | TW200613032A (pt) |
| WO (1) | WO2005123191A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9402852B2 (en) * | 2006-10-20 | 2016-08-02 | Children's Medical Center Corporation | Method to enhance tissue regeneration |
| CN102124000B (zh) | 2008-06-17 | 2014-09-17 | 阿斯利康(瑞典)有限公司 | 吡啶化合物 |
| US8722075B2 (en) | 2008-10-24 | 2014-05-13 | Warsaw Orthopedic, Inc. | Compositions and methods for promoting bone formation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254595A (en) * | 1988-12-23 | 1993-10-19 | Elf Sanofi | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them |
| US5837815A (en) * | 1994-12-15 | 1998-11-17 | Sugen, Inc. | PYK2 related polypeptide products |
| US5837524A (en) * | 1994-12-15 | 1998-11-17 | Sugen, Inc. | PYK2 related polynucleotide products |
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| UA51676C2 (uk) * | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
| UA59384C2 (uk) * | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| AU6163398A (en) * | 1997-02-11 | 1998-08-26 | Merck & Co., Inc. | Identification of inhibitors of protein tyrosine kinase 2 |
| US6124314A (en) * | 1997-10-10 | 2000-09-26 | Pfizer Inc. | Osteoporosis compounds |
| UA67754C2 (uk) * | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
| US20030191162A1 (en) * | 1998-12-31 | 2003-10-09 | Sugen Inc. | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| CA2529611C (en) * | 2002-12-20 | 2009-12-15 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
-
2005
- 2005-06-10 BR BRPI0512342-9A patent/BRPI0512342A/pt not_active IP Right Cessation
- 2005-06-10 US US11/570,815 patent/US20090118316A1/en not_active Abandoned
- 2005-06-10 WO PCT/IB2005/002127 patent/WO2005123191A1/en not_active Ceased
- 2005-06-10 EP EP05779792A patent/EP1765461A1/en not_active Withdrawn
- 2005-06-10 CA CA002571482A patent/CA2571482A1/en not_active Abandoned
- 2005-06-10 MX MXPA06015170A patent/MXPA06015170A/es not_active Application Discontinuation
- 2005-06-10 JP JP2007517527A patent/JP2008503561A/ja not_active Withdrawn
- 2005-06-17 AR ARP050102506A patent/AR049922A1/es unknown
- 2005-06-17 TW TW094120300A patent/TW200613032A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005123191A1 (en) | 2005-12-29 |
| CA2571482A1 (en) | 2005-12-29 |
| TW200613032A (en) | 2006-05-01 |
| JP2008503561A (ja) | 2008-02-07 |
| MXPA06015170A (es) | 2007-08-21 |
| AR049922A1 (es) | 2006-09-13 |
| US20090118316A1 (en) | 2009-05-07 |
| EP1765461A1 (en) | 2007-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pilloni et al. | Evaluation of the efficacy of an hyaluronic acid-based biogel on periodontal clinical parameters. A randomized-controlled clinical pilot study | |
| Nuhr et al. | Functional and biochemical properties of chronically stimulated human skeletal muscle | |
| WO2005112981A3 (en) | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells | |
| BRPI0810336A2 (pt) | "método para tratar e/ou prevenir úlceras de pele em um indivíduo" | |
| BRPI0518086A (pt) | métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação | |
| ATE489957T1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
| DE60312309D1 (de) | Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten | |
| NO20044462L (no) | Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer | |
| MX2009010557A (es) | Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas. | |
| MY158100A (en) | 6,9-disubstituted purine derivatives and their use for treating skin | |
| EA201000265A1 (ru) | Мутанты mcp-1 антагонисты гликозаминогликана и способы их применения | |
| ATE381336T1 (de) | Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten | |
| TR201903587T4 (tr) | Telomeraz aktivitesinin artırılması için bileşimler. | |
| EP1543158A4 (en) | REGULATED APTAMER THERAPEUTICS | |
| Gobbo et al. | Evaluation of nutritional status in head and neck radio-treated patients affected by oral mucositis: efficacy of class IV laser therapy | |
| MX2010010799A (es) | Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea. | |
| ATE446102T1 (de) | Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii | |
| DE602005010876D1 (de) | Neuartige biaromatische ppar-rezeptoren aktivierende zusammensetzungen und ihre verwendung in kosmetischen oder pharmazeutischen zusammensetzungen | |
| EA201000630A1 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови | |
| NO20070996L (no) | Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelser | |
| Kubala et al. | Multidisciplinary and nonpharmacological management of pain in temporomandibular disorders (TMDs) | |
| Wang et al. | The differential effects of depression on evoked and spontaneous pain behaviors in olfactory bulbectomized rats | |
| BRPI0512342A (pt) | métodos para aumento ósseo | |
| DE602004022266D1 (de) | Lkarzinoms der blase | |
| BR0308415A (pt) | Métodos de tratamento de diabetes usando-se inibidores de pde11a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |
|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 31/00 (2006.01), A61P 19/08 (2006.01), A61P 1 |